Leerink notes Eli Lilly’s (LLY) once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made by Novo Nordisk (NVO). Importantly, the press release stated that “no hepatic safety signal was observed.” The firm expects the next orforglipron Phase 3 topline result in Q3 2025, and it expects orforglipron to be approved in 2026. Leerink reiterates an Outperform rating on Eli Lilly’s shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Morning Movers: UnitedHealth plummets following Q1 results and guidance cut
- Eli Lilly Stock (LLY) Goes Supersize after New Oral Weight Loss Drug Impresses in Trials
- Eli Lilly data show orforglipron ‘highly competitive,’ says JPMorgan
- Viking Therapeutics slips after Eli Lilly reports orforglipron trial results
- Eli Lilly announces ACHIEVE-1 trial met primary endpoint